FDA Brief

Warning letters Drugs

FDA warning letter to

Salon Technologies International, Inc.

High riskIssued Dec 21, 2022Posted Feb 7, 2023Division of Pharmaceutical Quality Operations II

FDA warns Salon Technologies International that its hand sanitizers contained unacceptable acetaldehyde, acetal and benzene impurities and were adulterated.

What happened

FDA conducted laboratory testing of a batch of Salon Technologies International Sanitizing Hand Spray 80% in U.S. distribution and found acetaldehyde and acetal at about 739 ppm and 988 ppm. After FDA's June 24, 2022 letter, the firm provided retain-sample impurity results on September 2, 2022, showing benzene at about 12 ppm in Antica Farmacista Hand Sanitizer Ocean Citron. On September 17, 2022, the firm issued a voluntary nationwide recall of one lot of each product.

What FDA found

  1. FDA laboratory testing of a U.S.-distributed batch of Salon Technologies International Sanitizing Hand Spray 80% found acetaldehyde and acetal at about 739 ppm and 988 ppm, above the USP limit of 10 ppm.

    section 501(a)(2)(B) of the FD&C Act; 21 CFR 211.160(b); 21 CFR 211.165
  2. The firm's own retain-sample test results for Antica Farmacista Hand Sanitizer Ocean Citron found benzene at about 12 ppm.

    section 501(a)(2)(B) of the FD&C Act
  3. The firm did not test active pharmaceutical ingredients or finished hand sanitizer for acetal, acetaldehyde, or benzene before distribution.

    21 CFR 211.160(b); 21 CFR 211.165
  4. The firm lacked a finished-product specification for acetaldehyde and acetal even though alcohol is a significant component of the drug product.

    21 CFR 211.160(b)
  5. The firm did not perform finished-product testing of each batch for acetaldehyde, acetal, and benzene.

    21 CFR 211.165

What FDA wants

FDA tells the firm to respond in writing within 15 working days with a detailed impurity investigation, a list of all raw materials and suppliers, and complete batch records for all U.S.-distributed batches, and to correct violations promptly; FDA also recommends a qualified current good manufacturing practice (CGMP) consultant if the firm resumes U.S. drug manufacturing.

Who should pay attention

  • brands that buy finished hand sanitizer from contract manufacturers
  • retailers and distributors selling hand sanitizers
  • drug manufacturers using alcohol ingredients with impurity risks

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk